エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2026
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on May 1, 2026 titled:
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
“Financial Services and Company Secretary Changes”
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
EXHIBITS
| Exhibit Number |
Description | |
| 99.1 | Financial Services and Company Secretary Changes |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RADIOPHARM THERANOSTICS LIMITED | ||
| Date: May 1, 2026 | By: | /s/ Nathan Jong |
| Nathan Jong | ||
| Company Secretary | ||
Exhibit 99.1
|
ASX ANNOUNCEMENT 1 May 2026 |
 |
Financial Services and Company Secretary Changes
Sydney, Australia – 1 May 2026 – Radiopharm Theranostics (ASX: RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs advises, provides an update in accordance with ASX Listing Rule 3.16.1.
As disclosed in the Company’s annual reporting, it has a continuing agreement with Acclime Australia to provide company secretarial, CFO and statutory reporting, accounting and financial management, bookkeeping and payroll processing services. Under this agreement, Mr Phillip Hains was engaged as Chief Financial Officer and Joint Company Secretary.
The Company advises that Mr Hains has resigned from his roles as Chief Financial Officer and Joint Company Secretary. The Board thanks Mr Hains for his contribution to the Company and wishes him well in his future plans.
The Company will continue to engage Acclime Australia to provide these services, and Acclime Australia has nominated Mr Aaron Laurita to perform the responsibilities of Chief Financial Officer. Mr Laurita brings strong finance and commercial expertise, developed through working with organisations across several sectors, including the biotechnology sector, in Australia, the United States and Canada over the past decade. Mr Laurita holds a Bachelor of Business (Professional Accountancy) from RMIT University and is a qualified Chartered Accountant and a member of Chartered Accountants Australia and New Zealand.
The Company is also pleased to announce the appointment of Ms Amritha Sushil of Acclime Australia as Joint Company Secretary. Ms Sushil has extensive experience in corporate governance and compliance, and the Board looks forward to her support in this role. Ms Sushil is a Chartered Secretary and an Associate of the Governance Institute of Australia.
Mr Nathan Jong of Acclime Australia continues in his role as a Joint Company Secretary.
For the purposes of ASX Listing Rule 12.6, the Company confirms that Ms Amritha Sushil and Mr Nathan Jong will serve as Joint Company Secretaries and will be responsible for communications between the Company and ASX.
These changes take effect immediately.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
Riccardo Canevari CEO & Managing Director P: +1 862 309 0293 E: rc@radiopharmtheranostics.com Precision AQ (Formerly Stern IR)
Radiopharm
Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
|
ASX ANNOUNCEMENT 1 May 2026 |
|
Anne Marie Fields
E: annemarie.fields@precisionaq.com
Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889